Search research articles
Contact Us
Filters
Showing results (251-260 of 283) with videos related to
Page
of 29
Sort By:
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
April 16, 2025
Postoperative Outcomes in Tofacitinib-Treated Patients With Acute Severe Ulcerative Colitis Undergoing Colectomy
Charlotte Larson, Jeffrey A Berinstein, Nicholas Tedesco, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
June 5, 2021
Biomarkers for the Prediction and Diagnosis of Fibrostenosing Crohn's Disease: A Systematic Review
Calen A Steiner, Jeffrey A Berinstein, Jeremy Louissaint, et al.
Gastroenterology
|
November 8, 2021
Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn's Disease
Bruce E Sands, Laurent Peyrin-Biroulet, Jaroslaw Kierkus, et al.
The American Journal of Pathology
|
February 15, 2015
Inhibition of myocardin-related transcription factor/serum response factor signaling decreases lung fibrosis and promotes mesenchymal cell apoptosis
Thomas H Sisson, Iyabode O Ajayi, Natalya Subbotina, et al.
The American Journal of Gastroenterology
|
January 9, 2013
Does rectal indomethacin eliminate the need for prophylactic pancreatic stent placement in patients undergoing high-risk ERCP? Post hoc efficacy and cost-benefit analyses using prospective clinical trial data
B Joseph Elmunzer, Peter D R Higgins, Sameer D Saini, et al.
The American Journal of Gastroenterology
|
May 7, 2019
Serum Protein Biomarkers of Fibrosis Aid in Risk Stratification of Future Stricturing Complications in Pediatric Crohn's Disease
Jing Wu, David M Lubman, Subra Kugathasan, et al.
Alimentary Pharmacology & Therapeutics
|
November 27, 2023
Efficacy and safety of upadacitinib for 16-week extended induction and 52-week maintenance therapy in patients with moderately to severely active ulcerative colitis
Remo Panaccione, Silvio Danese, Wen Zhou, et al.
Gastroenterology
|
April 10, 2017
Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn's Disease: A Phase 2a Study
Bruce E Sands, Jingjing Chen, Brian G Feagan, et al.
The American Journal of Gastroenterology
|
December 6, 2012
Development of the Paris definition of early Crohn's disease for disease-modification trials: results of an international expert opinion process
Laurent Peyrin-Biroulet, Vincent Billioud, Geert D'Haens, et al.
Cell
|
May 21, 2021
Charting human development using a multi-endodermal organ atlas and organoid models
Qianhui Yu, Umut Kilik, Emily M Holloway, et al.
Page
of 29
Search research articles
Search
Showing results (251-260 of 283) with videos related to
Sort By:
Page
of 29
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
April 16, 2025
Postoperative Outcomes in Tofacitinib-Treated Patients With Acute Severe Ulcerative Colitis Undergoing Colectomy
Charlotte Larson, Jeffrey A Berinstein, Nicholas Tedesco, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
June 5, 2021
Biomarkers for the Prediction and Diagnosis of Fibrostenosing Crohn's Disease: A Systematic Review
Calen A Steiner, Jeffrey A Berinstein, Jeremy Louissaint, et al.
Gastroenterology
|
November 8, 2021
Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn's Disease
Bruce E Sands, Laurent Peyrin-Biroulet, Jaroslaw Kierkus, et al.
The American Journal of Pathology
|
February 15, 2015
Inhibition of myocardin-related transcription factor/serum response factor signaling decreases lung fibrosis and promotes mesenchymal cell apoptosis
Thomas H Sisson, Iyabode O Ajayi, Natalya Subbotina, et al.
The American Journal of Gastroenterology
|
January 9, 2013
Does rectal indomethacin eliminate the need for prophylactic pancreatic stent placement in patients undergoing high-risk ERCP? Post hoc efficacy and cost-benefit analyses using prospective clinical trial data
B Joseph Elmunzer, Peter D R Higgins, Sameer D Saini, et al.
The American Journal of Gastroenterology
|
May 7, 2019
Serum Protein Biomarkers of Fibrosis Aid in Risk Stratification of Future Stricturing Complications in Pediatric Crohn's Disease
Jing Wu, David M Lubman, Subra Kugathasan, et al.
Alimentary Pharmacology & Therapeutics
|
November 27, 2023
Efficacy and safety of upadacitinib for 16-week extended induction and 52-week maintenance therapy in patients with moderately to severely active ulcerative colitis
Remo Panaccione, Silvio Danese, Wen Zhou, et al.
Gastroenterology
|
April 10, 2017
Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn's Disease: A Phase 2a Study
Bruce E Sands, Jingjing Chen, Brian G Feagan, et al.
The American Journal of Gastroenterology
|
December 6, 2012
Development of the Paris definition of early Crohn's disease for disease-modification trials: results of an international expert opinion process
Laurent Peyrin-Biroulet, Vincent Billioud, Geert D'Haens, et al.
Cell
|
May 21, 2021
Charting human development using a multi-endodermal organ atlas and organoid models
Qianhui Yu, Umut Kilik, Emily M Holloway, et al.
Page
of 29